Altering potassium channel activity to investigate morphine tolerance and opiate induced hypersensitivity

改变钾通道活性以研究吗啡耐受性和阿片类药物引起的超敏反应

基本信息

  • 批准号:
    10349435
  • 负责人:
  • 金额:
    $ 14.2万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-03-01 至 2023-02-28
  • 项目状态:
    已结题

项目摘要

7. Project Summary/Abstract This proposal is for a K01 Mentored Research Scientist Development Award for Dr. Amanda Klein, Assistant Professor in the Department of Pharmacy Practice and Pharmaceutical Sciences at the University of Minnesota. The K01 award will provide Dr. Klein with the additional training and experience necessary to become an independent investigator studying the effects of opioid tolerance and withdrawal in the peripheral and central nervous system. Dr. Carolyn Fairbanks will serve as the primary mentor with expertise in drug delivery methods and opioid tolerance, and will oversee the training plan. Dr. Lucy Vulchanova will provide additional mentorship and has extensive experience in central nervous system imaging methods during chronic pain conditions. The proposed career development plan includes focused workshops and seminars, mentorship from a group of established researchers, and the attainment novel research skills. The long term goal of this K01 career award is effectively study the mechanisms that lead to opioid tolerance and withdrawal and to establish therapeutic targets for chronic pain patients current on opioid medications. Opioid therapy has been shown to be effective in reducing chronic pain in the clinic; unfortunately, long term treatment has negative consequences, including sedation, tolerance, abuse potential and opioid induced hyperalgesia (OIH) when treatment is stopped. Opioid tolerance is potentially due to receptor desensitization and/or a functional uncoupling of opioid receptors from their effector systems. Previous literature suggests that mechanisms of opioid tolerance, and OIH after opioid treatment has ceased, can be driven by changes in the peripheral nervous system (PNS) and central nervous system (CNS). Potassium channels, such as ATP sensitive potassium channels (KATP channels) are expressed on peripheral nociceptors and second order neurons, and contribute to the analgesic properties of opioids as downstream effectors. The proposed behavioral, electrophysiological, and imaging methods are essential in order to understand the role of KATP channels subtypes before and after opioid tolerance. The research objectives of this K01 award are to: 1) Identify the involvement of KATP channels in the PNS and CNS in the maintenance of neuropathic pain during morphine tolerance and 2) Quantify the changes in location, expression and function of KATP channel subtypes in peripheral (nerve fibers) versus central (spinal cord) nervous system before and after prolonged opioid exposure. Preliminary data suggest that a decrease in activity of specific KATP channel subtypes in the PNS versus the CNS contribute to opioid tolerance. Future experiments will further investigate the diverse intracellular pathways leading to changes in KATP channel expression and function in the PNS and CNS. The ultimate goal is to use KATP channel targeting pharmaceutics to improve chronic pain conditions while alleviating tolerance and OIH in humans and therefore decrease the adverse side effects seen with many existing opioid therapies.
7。项目摘要/摘要 该建议是为助理Amanda Klein博士的K01指导研究科学家发展奖。 大学药学实践和药学系教授 明尼苏达州。 K01奖将为Klein博士提供所需的额外培训和经验 成为研究阿片类药物耐受性和戒断的影响的独立研究者 和中枢神经系统。卡罗琳·费尔班克斯(Carolyn Fairbanks)博士将担任具有毒品专业知识的主要导师 交付方法和阿片类药物耐受性,并将监督培训计划。露西·瓦查诺娃(Lucy Vulchanova)博士将提供 额外的指导,在慢性期间具有丰富的中枢神经系统成像方法的经验 疼痛条件。拟议的职业发展计划包括专注的研讨会和研讨会, 一群知名研究人员的指导以及成就新颖的研究技能。长期 这个K01职业奖的目标有效地研究了导致阿片类药物耐受性和戒断的机制 并为阿片类药物的慢性疼痛患者建立治疗靶标。阿片类药物疗法具有 被证明可有效减轻临床的慢性疼痛;不幸的是,长期治疗有 负面后果,包括镇静,耐受性,滥用潜力和阿片类药物诱导的痛觉过敏(OIH) 当治疗停止时。 阿片类药物的耐受性可能是由于受体脱敏和/或功能 从其效应器系统中解开阿片类药物受体。 以前的文献表明 阿片类药物治疗后的阿片类药物耐受性和OIH停止后,外围的变化可以驱动 神经系统(PNS)和中枢神经系统(CNS)。钾通道,例如ATP敏感 钾通道(KATP通道)在外围伤害感受器和二阶神经元上表达,并且 有助于阿片类药物作为下游效应子的镇痛特性。提出的行为, 电生理和成像方法对于了解KATP通道的作用至关重要 阿片类药物耐受性前后的亚型。该K01奖的研究目标是:1)确定 在吗啡期间,KATP通道参与PNS和CNS的神经性疼痛 公差和2)量化Katp通道亚型的位置,表达和功能的变化 延长阿片类药物之前和之后,周围(神经纤维)与中心(脊髓)神经系统 接触。初步数据表明,PNS中特定KATP通道亚型的活性减少 与中枢神经系统有助于阿片类药物耐受性。未来的实验将进一步研究多样的 细胞内途径导致PNS和CNS中KATP通道表达和功能的变化。这 最终目标是使用靶向药物的KATP通道来改善慢性疼痛状况 减轻人类的耐受性和OIH,因此减少了许多人看到的不利副作用 现有的阿片类药物疗法。

项目成果

期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Reduced activity of adenylyl cyclase 1 attenuates morphine induced hyperalgesia and inflammatory pain in mice.
  • DOI:
    10.3389/fphar.2022.937741
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    5.6
  • 作者:
    Johnson, Kayla;Doucette, Alexis;Edwards, Alexis;Verdi, Aleeya;McFarland, Ryan;Hulke, Shelby;Fowler, Amanda;Watts, Val J.;Klein, Amanda H.
  • 通讯作者:
    Klein, Amanda H.
KATP Channel Prodrugs Reduce Inflammatory and Neuropathic Hypersensitivity, Morphine-Induced Hypersensitivity, and Precipitated Withdrawal in Mice.
KATP 通道前药可减轻小鼠的炎症和神经性超敏反应、吗啡引起的超敏反应和突然戒断反应。
Inhibition of the phosphoinositide 3-kinase-AKT-cyclic GMP-c-Jun N-terminal kinase signaling pathway attenuates the development of morphine tolerance in a mouse model of neuropathic pain.
  • DOI:
    10.1177/17448069211003375
  • 发表时间:
    2021-01
  • 期刊:
  • 影响因子:
    3.3
  • 作者:
    Okerman T;Jurgenson T;Moore M;Klein AH
  • 通讯作者:
    Klein AH
Loss of SUR1 subtype KATP channels alters antinociception and locomotor activity after opioid administration.
SUR1 亚型 KATP 通道的丧失会改变阿片类药物给药后的镇痛和运动活性。
  • DOI:
    10.1016/j.bbr.2021.113467
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    2.7
  • 作者:
    Sakamaki,Gerald;Johnson,Kayla;Mensinger,Megan;Hmu,Eindray;Klein,AmandaH
  • 通讯作者:
    Klein,AmandaH
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Amanda Helen Klein其他文献

Amanda Helen Klein的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Amanda Helen Klein', 18)}}的其他基金

KATP Channels as Downstream targets of adenylyl cyclases during opioid tolerance and withdrawal
KATP 通道作为阿片类药物耐受和戒断期间腺苷酸环化酶的下游靶标
  • 批准号:
    10451672
  • 财政年份:
    2021
  • 资助金额:
    $ 14.2万
  • 项目类别:
KATP Channels as Downstream targets of adenylyl cyclases during opioid tolerance and withdrawal
KATP 通道作为阿片类药物耐受和戒断期间腺苷酸环化酶的下游靶标
  • 批准号:
    10317189
  • 财政年份:
    2021
  • 资助金额:
    $ 14.2万
  • 项目类别:
KATP Channels as Downstream targets of adenylyl cyclases during opioid tolerance and withdrawal
KATP 通道作为阿片类药物耐受和戒断期间腺苷酸环化酶的下游靶标
  • 批准号:
    10618258
  • 财政年份:
    2021
  • 资助金额:
    $ 14.2万
  • 项目类别:
Altering potassium channel activity to investigate morphine tolerance and opiate induced hypersensitivity
改变钾通道活性以研究吗啡耐受性和阿片类药物引起的超敏反应
  • 批准号:
    10088427
  • 财政年份:
    2018
  • 资助金额:
    $ 14.2万
  • 项目类别:
Mechanisms of analgesia by peripheral viral vector insertion of opioid receptors.
阿片受体外周病毒载体插入的镇痛机制。
  • 批准号:
    8780191
  • 财政年份:
    2014
  • 资助金额:
    $ 14.2万
  • 项目类别:

相似海外基金

Maintaining opioid analgesia and preventing addiction with hypocretin antagonism
通过下丘脑分泌素拮抗作用维持阿片类药物镇痛并预防成瘾
  • 批准号:
    10713175
  • 财政年份:
    2023
  • 资助金额:
    $ 14.2万
  • 项目类别:
High content analgesic screening from human nociceptors
从人类伤害感受器中筛选高含量镇痛剂
  • 批准号:
    10578042
  • 财政年份:
    2023
  • 资助金额:
    $ 14.2万
  • 项目类别:
Role of Primary Sensory Neuron CaMKII Signaling in Regulation of Pain
初级感觉神经元 CaMKII 信号传导在疼痛调节中的作用
  • 批准号:
    10656886
  • 财政年份:
    2023
  • 资助金额:
    $ 14.2万
  • 项目类别:
Targeting visceral pain through intestinal neuropod cell GUCY2C signaling
通过肠道神经足细胞 GUCY2C 信号传导治疗内脏疼痛
  • 批准号:
    10837293
  • 财政年份:
    2023
  • 资助金额:
    $ 14.2万
  • 项目类别:
CaV2.2 splice variants in the hippocampus: function and pharmacology
海马 CaV2.2 剪接变异体:功能和药理学
  • 批准号:
    10363116
  • 财政年份:
    2022
  • 资助金额:
    $ 14.2万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了